Find a Researcher

Close

Filter Selection By:

Area Of Focus

Research Center

Hanno Steen, PhD
LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Hanno  Steen, PhD

Department: Pathology
Research Centers: Pathology Research Center
Hospital Title: Director of the Proteomics Center
Academic Title: Associate Professor of Pathology, Harvard Medical School
Research Area: Proteomics

Contact:

617-919-2629

Research Overview

Hanno Steen is a pioneer in developing methods for the qualitative and quantitative analysis of protein modifications by mass spectrometry, with special emphasis on tyrosine phosphorylation. In carcinogenesis, the pivotal role of tyrosine phosphorylation is underscored by the notion that almost half of the oncogenes known to date encode tyrosine kinases.

Hanno Steen's interests are focused on proteomics and biological mass spectrometry in general. He is particularly interested in the mass spectrometric analysis of the composition of complex protein mixtures, which includes not only the cataloging but also the comprehensive characterization of the components.

Dr. Steen's lab is working on novel methods for identifying and quantifying various protein modifications that are involved in pediatric diseases in order to provide new insights into the underlying biological processes, a prerequisite for a rational approach to prevent and/or cure these diseases.

Another goal of the lab's research is the development and applications of screening methods to detect and identify diagnostic and prognostic disease markers in body fluids, which offer an easily accessible mirror of the state of the entire body. These biomarkers can guide treatment decisions, predict patient phenotypes, and allow for early diagnosis.

About Hanno Steen

Dr. Steen studied chemistry at the University in Freiburg (Germany), UMIST/Manchester (UK) and Swiss Federal Institute of Technology (ETH) Zurich (Switzerland). He received his PhD in Biochemistry and Molecular Biology from the University of Southern Denmark working in the laboratory of Matthias Mann on the mass spectrometric analysis of protein modifications. He completed postdoctoral fellowships in the laboratories of Steve Gygi and Marc Kirschner at the Departments of Cell Biology and Systems Biology at Harvard Medical School.

Key Publications

  • Singh SA, Winter D, Bilimoria PM, Bonni A, Steen H*, Steen JA*. FLEXIQinase, a mass spectrometry-based assay, to unveil multikinase mechanisms. Nat Methods. 2012:9:504-508. PMID: 22484849.
     
  • Wilhelm M, Kirchner M, Steen J, Steen H. mz5: Space- and Time-Efficient Storage of Mass Spectrometry Data Sets. Mol Cell Proteomics. 2012 Jan;11(1):O111.011379. PMID: 21960719
     
  • Broadbelt KG, Rivera KD, Paterson DS, Duncan JR, Trachtenberg FL, Paulo JA, Stapels MD, Borenstein NS, Belliveau RA, Haas EA, Stanley C, Krous HF, Steen H*, Kinney HC*. Brainstem Deficiency of the 14-3-3 Regulator of Serotonin Synthesis: A Proteomics Analysis in the Sudden Infant Death Syndrome. Mol Cell Proteomics. 2012 Jan;11(1):M111.009530. PMID: 21976671
     
  • Prabakaran S, Everley RA, Landrieu I, Wieruszeski JM, Lippens G*,Steen H*, Gunawardena J*. Comparative analysis of Erk phosphorylation suggests a mixed strategy for measuring phospho-form distributions. Mol Syst Biol. 2011 Apr 12;7:482. 
     
  • Prisic S, Dankwa S, Schwartz D, Chou MF, Locasale JW, Kang CM, Bemis G, Church GM, Steen H, Husson RN. Extensive phosphorylation with overlapping specificity by Mycobacterium tuberculosis serine/threonine protein kinases. Proc Natl Acad Sci U S A. 2010;107(16):7521-6. PMID: 20368441.
     
  • Kentsis A, Lin YY, Kurek K, Calicchio M, Wang YY, Monigatti F, Campagne F, Lee R, Horwitz B, Steen H*, Bachur R*. Discovery and Validation of Urine Markers of Acute Pediatric Appendicitis Using High-Accuracy Mass Spectrometry. Ann Emerg Med. 2010;55(1):62-70. PMID: 19556024
     
  • further publications can be found here

Related Research CentersMore

Related Research LabsMore

The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO
Close